ArticleCureus2025
Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Skin scars, a natural outcome of dermal injury healing, may seem minor but often lead to significant disfigurement and psychological distress. This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate. This synergistic formulation targets multiple scar-improvement mechanisms, offering potential for enhanced skin texture and minimized scar appearance. Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars. Ethical approval was granted by the Independent Ethics Committee, and informed consent was obtained from all participants. Visible scar changes were assessed using the Manchester Scoring Scale by a dermatologist. Skin texture changes, including smoothness, roughness, and scaliness, were evaluated using VISIOSCAN® VC20 Plus (Courage + Khazaka electronic GmbH, Cologne, Germany). Digital photographs documented progressive scar visibility reduction. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0.1.0 (Released 2022; IBM Corp., Armonk, New York) and Microsoft® Excel 2019 (Microsoft Corporation, Redmond, Washington), with significance reported at the 5% level. Result The test product reduced scar appearance by 7.17% at day 21 (p<0.001) and 26.57% at day 45 (p<0.0001). Skin smoothness improved by 33.08% at day 21 (p<0.0001) and 44.56% at day 45 (p<0.0001). Skin roughness decreased by 100.86% at day 21 (p<0.0001) and 161.62% at day 45 (p<0.0001). Scaliness reduced by 39.71% at day 21 (p<0.001) and 58.92% at day 45 (p<0.0001). No local or systemic adverse effects were reported. Conclusion ThriveCo Scar Fader Gel with Scarcede™ demonstrated clinical safety and efficacy in scar reduction, supporting smoother, clearer skin without adverse effects and suitable for routine skincare use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.